Predictive Factors of Early Recurrence of Pancreatic Adenocarcinoma After Curative Resection Surgery
DOI:
https://doi.org/10.55175/cdk.v51i6.965Keywords:
Pancreatic adenocarcinoma, predictive factors, recurrence, resectionAbstract
Introduction: Pancreatic adenocarcinoma stands as one of the most devastating forms of cancer, with a survival rate of less than 5% after 5 years. Despite resection surgery being the only curative option, recurrence occurs in up to 85% of cases. It is crucial to identify factors that can accurately predict the probability of recurrence for more effective management strategies. Method: Following the PRISMA guidelines, a systematic review was carried out by extracting relevant studies from the PubMed MEDLINE database. Results: A total of 1,345 studies were initially identified, and 34 studies were analyzed. A total of thirty-five predictive factors were identified and classified into preoperative and postoperative categories. These factors were be further subdivided into patient characteristics, biomarkers, tumor characteristics, and genetics. The most frequently observed factors were lymph node metastasis, serum CA 19-9 level, and tumor size. Conclusion: Preoperative and postoperative patient characteristics, genetics, biomarkers, and tumor characteristics data can be utilized to predict and implement suitable follow-up strategies aimed at enhancing patient survival rates.
Downloads
References
Pourhoseingholi MA, Ashtari S, Hajizadeh N, Fazeli Z, Zali MR. Systematic review of pancreatic cancer epidemiology in Asia-Pacific Region: Major patterns in GLOBACON 2012. Gastroenterol Hepatol Bed Bench. 2017;10(4):245-57.
Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63.
Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:56-68.
Rishi A, Goggins M, Wood LD, Hruban RH. Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol. 2015;42(1):28-39.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25(8):1650-6.
Padmomartono F. Tumor pankreas. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editors. Buku ajar ilmu penyakit dalam. 5th Ed. Jakarta: Pusat Penerbitan Departemen Ilmu Penyakit Dalam FKUI; 2009 .p. 739-46.
Mayer R. Pancreatic cancer. In: Kasper DL, Braunwald E, editors. Harrison’s principles of internal medicine. 16th Ed. New York: Mc Graw-Hill; 2005 .p. 537-9.
Neoptolemos J, Stocken D, Smith CT, Bassi C, Ghaneh P, Owen E, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: Composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer 2009;100(2):246-50.
Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: Results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol. 2008;26(21):3503-10.
Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, et al. Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: Is cure possible? Ann Surg. 2008;247(3):456-62.
Page JM, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CK, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;327:n71.
Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assesing the quality of non-randomised studies in meta-analysis. The Ottawa Hospital Research Institute [Internet]. 2021 [cited 2023 Jan 8]. Available from: https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Aoyama T, Yamamoto N, Kamiya M, Murakawa M, Tamagawa H, Sawazaki S, et al. The lymph node ratio is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapy. Anticancer Res. 2018;38(8):4877-82.
Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(6):1154-62.
La Torre M, Nigri G, Lo Conte A, Mazzuca F, Tierno SM, Salaj A, et al. Is a preoperative assessment of the early recurrence of pancreatic cancer possible after complete surgical resection? Gut Liver 2014;8(1):102-8.
Wang T, Wentz SC, Ausborn NL, Washington MK, Merchant N, Zhao Z, et al. Pattern of breast cancer susceptibility gene 1 expression is a potential prognostic biomarker in resectable pancreatic ductal adenocarcinoma. Pancreas 2013;42(6):977-82.
Shirai Y, Shiba H, Sakamoto T, Horiuchi T, Haruki K, Fujiwara Y, et al. Preoperative platelet to lymphocyte ratio predicts outcome of patients with pancreatic ductal adenocarcinoma after pancreatic resection. Surgery 2015;158(2):360-5.
Okumura S, Kaido T, Hamaguchi Y, Kobayashi A, Shirai H, Yao S, et al. Visceral adiposity and sarcopenic visceral obesity are associated with poor prognosis after resection of pancreatic cancer. Ann Surg Oncol. 2017;24(12):3732-40.
Maréchal R, Demetter P, Nagy N, Berton A, Decaestecker C, Polus M, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma. Br J Cancer 2009;100(9):1444-51.
Chen T, Zhang MG, Xu HX, Wang WQ, Liu L, Yu XJ. Preoperative serum CA125 levels predict the prognosis in hyperbilirubinemia patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore) 2015;94(19):e751.
Motoi F, Murakami Y, Okada KI, Matsumoto I, Uemura K, Satoi S, et al. Sustained elevation of postoperative serum level of carbohydrate antigen 19-9 is high-risk stigmata for primary hepatic recurrence in patients with curatively resected pancreatic adenocarcinoma. World J Surg. 2019;43(2):634-41.
Hendifar A, Osipov A, Khanuja J, Nissen N, Naziri J, Yang W, et al. Influence of body mass index and albumin on perioperative morbidity and clinical outcomes in resected pancreatic adenocarcinoma. PLoS One 2016;11(3):e0152172.
Fleming JB, Gonzalez RJ, Petzel MQ, Lin E, Morris JS, Gomez H, et al. Influence of obesity on cancer-related outcomes after pancreatectomy to treat pancreatic adenocarcinoma. Arch Surg. 2009;144(3):216-21.
Vashist YK, Uzungolu G, Kutup A, Gebauer F, Koenig A, Deutsch L, et al. Heme oxygenase-1 germ line GTn promoter polymorphism is an independent prognosticator of tumor recurrence and survival in pancreatic cancer. J Surg Oncol. 2011;104(3):305-11.
Matsumoto I, Murakami Y, Shinzeki M, Asari S, Goto T, Tani M, et al. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center retrospective study. Pancreatology 2015;15(6):674-80.
Ling Q, Xu X, Ye P, Xie H, Gao F, Hu Q, et al. The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. Oncotarget. 2017;8(9):15159-67.
Lee SH, Kim H, Hwang JH, Shin E, Lee HS, Hwang DW, et al. CD24 and S100A4 expression in resectable pancreatic cancers with earlier disease recurrence and poor survival. Pancreas 2014;43(3):380-8.
Shiba H, Misawa T, Fujiwara Y, Futagawa Y, Furukawa K, Haruki K, et al. Negative impact of fresh-frozen plasma transfusion on prognosis of pancreatic ductal adenocarcinoma after pancreatic resection. Anticancer Res. 2013;33(9):4041-7.
Takahasi K, Iinuma H, Wada K, Minezaki S, Kawamura S, Kainuma M, et al. Usefulness of exosome-encapsulated microRNA-451a as a minimally invasive biomarker for prediction of recurrence and prognosis in pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2018;25(2):155-61.
Xu HX, Liu L, Xiang JF, Wang WQ, Qi ZH, Wu CT, et al. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels
Okamoto K, Koyama I, Miyazawa M, Toshimitsu Y, Aikawa M, Okada K, et al. Preoperative 18[F]-fluorodeoxyglucose positron emission tomography/computed tomography predicts early recurrence after pancreatic cancer resection. Int J Clin Oncol. 2011;16(1):39-44.
Balzano G, Dugnani E, Gandolfi A, Scavini M, Pasquale V, Aleotti F, et al. Effect of diabetes on survival after resection of pancreatic adenocarcinoma. A prospective, observational study. PLoS One 2016;11(11):e0166008.
Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, et al. CA19-9 on postoperative surveillance in pancreatic ductal adenocarcinoma: Predicting recurrence and changing prognosis over time. Ann Surg Oncol. 2018;25(12):3483-91.
Arima K, Yamashita YI, Hashimoto D, Nakagawa S, Umezaki N, Yamao T, et al. Clinical usefulness of postoperative C-reactive protein/albumin ratio in pancreatic ductal adenocarcinoma. Am J Surg. 2018;216(1):111-5.
Zhang SR, Yao L, Wang WQ, Xu JZ, Xu HX, Jin W, et al. Tumor-infiltrating platelets predict postsurgical survival in patients with pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2018;25(13):3984-93.
Ghaneh P, Kleeff J, Halloran CM, Raraty M, Jackson R, Melling J, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2017;269(3):520-9.
Johnson B, Khalil M, Blansfield J, Lin F, Zhu S, Kirchner HL, et al. Investigating the prognostic value of KOC (K homology domain containing protein overexpressed in cancer) overexpression after curative intent resection of pancreatic ductal adenocarcinoma. J Gastrointest Oncol. 2016;7(6):E113-e7.
Piro G, Simionato F, Carbone C, Frizziero M, Malleo G, Zanini S, et al. A circulating T(H)2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma. Oncoimmunology 2017;6(9):e1322242.
Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, et al. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(5):977-85.
Kim H, Park CY, Lee JH, Kim JC, Cho CK, Kim HJ. Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer. Ann Surg Treat Res. 2015;88(4):200-7.
Aoyama T, Atsumi Y, Kazama K, Murakawa M, Shiozawa M, Kobayashi S, et al. Survival and the prognosticators of peritoneal cytology-positive pancreatic cancer patients undergoing curative resection followed by adjuvant chemotherapy. J Cancer Res Ther. 2018;14:S1129-s34.
Cassinotto C, Chong J, Zogopoulos G, Reinhold C, Chiche L, Lafourcade JP, et al. Resectable pancreatic adenocarcinoma: Role of CT quantitative imaging biomarkers for predicting pathology and patient outcomes. Eur J Radiol. 2017;90:152-8.
Kim NH, Kim HJ. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection. Hepatobiliary Pancreat Dis Int. 2018;17(5):450-5.
Chen J, Zhou ZC, Liu WB, Wang J, Chen XJ, Shen YY, et al. Expression of B cell transposition gene 3 in pancreatic ductal adenocarcinoma and its prognostic value. Zhonghua Wai Ke Za Zhi. 2017;55(11):863-7.
Huang YK, Liu H, Wang XZ, Zhu S. Annexin A2 and CD105 expression in pancreatic ductal adenocarcinoma is associated with tumor recurrence and prognosis. Asian Pac J Cancer Prev. 2014;15(22):9921-6.
National Comprehensive Cancer Network. Pancreatic Adenocarcinoma [Internet]. Pennsylvania: National Comprehensive Cancer Network [Internet]. 2023 [cited 2023 Jan 8]. Available from: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1455.
Jones D, Pereira ER, Padera TP. Growth and immune evasion of lymph node metastasis. Front Oncol. 2018;8:36.
Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, et al. The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer. J Surg Res. 2007;140(1):31-5.
Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188–96
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Muhammad Faza Soelaeman, Favian Ariiq Rahmat, Aji Wahyu Wardhana
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
